摘要
目的探讨醋酸阿托西班联合盐酸利托君在先兆早产患者中的疗效。方法选择我院产科收治的先兆早产患者为研究对象,随机分为两组,每组46例。对照组采用盐酸利托君治疗,观察组采用盐酸利托君联合醋酸阿托西班治疗。对比两组宫缩抑制有效率、分娩方式及新生儿结局、血清相关指标及不良反应发生情况。结果观察组宫缩抑制有效率明显高于对照组(P<0.05),早产率明显低于对照组(P<0.05),新生儿体重明显高于对照组(P<0.05),剖宫产率和新生儿评分无明显差异(P>0.05),治疗后,两组血清炎性因子水平明显下降,观察组变化幅度高于对照组(P<0.05),且观察组不良反应发生情况明显低于对照组(P<0.05)。结论醋酸阿托西班联合盐酸利托君治疗早产,能改善患者的血清炎性因子水平,减轻炎症反应,延长妊娠时间,对改善妊娠结局效果更佳,且孕妇应用安全性好,值得临床推广应用。
Objective To explore the efficacy of atosiban acetate combined with ritodrine hydrochloride in patients with threatened preterm labor.Methods Patients with threatened preterm labor admitted to the obstetrics department of our hospital were selected as the subjects of the study and were randomly divided into two groups,with 46 cases in each group.The control group was treated with ritodrine hydrochloride,and the observation group was treated with a combination of ritodrine hydrochloride and atosibanacetate.The tocolysis efficacy rates,delivery modes,the success rate of fetal preservation,serum biomarkers and the incidence of adverse reactions were compared between the two groups.Results The observation group demonstrated statistically significant superiority in tocolysis efficacy rate(P<0.05),lower preterm birth rate(P<0.05),and higher neonatal birth weight(P<0.05)compared to the control group.No significant differences were observed in cesarean delivery rates or neonatal Apgar scores between these two groups(P>0.05).Post-treatment assessment revealed marked reductions in serum inflammatory cytokine levels in both groups,with the observation group exhibiting a greater magnitude of decrease(P<0.05).Additionally,the incidence of adverse reactions in the observation group was significantlly less than that in the control group(P<0.05).Conclusion The treatment of preterm labor with atosiban acetate combined with ritodrine hydrochloride can improve the levels of serum inflammatory factors,reduce their inflammatory response,effectively prolong the gestation period,and provide a better effect on improving the outcome of pregnancy.It is also safe for pregnant women and is worth promoting in clinical application.
作者
徐洁
陈小芳
蔡含蓉
黄丽琼
XU Jie;CHEN Xiao-fang;CAI Han-rong(Xianning Maternal and Child Health Care Hospital,Xianning Hubei 437100,China)
出处
《湖北科技学院学报(医学版)》
2025年第4期328-330,共3页
Journal of Hubei University of Science and Technology(Medical Sciences)
